

Letter to the Editor

Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease

To the Editor:

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by low immunoglobulin serum levels, low vaccine responses, and recurrent infections. The clinical presentation of CVID comprises a variable mixture of recurrent infections, autoimmune phenomena, granulomatous disease, and lymphoproliferation. The underlying genetic mechanisms have been elucidated in the last few years in less than 10% to 15% of the cases and involve mutations in *CD19*, *MS4A1* (CD20), *CR2* (CD21), *ICOS*, *TNFRSF13C*, *TNFRSF13B*, *PLCG2* (phospholipase Cg2), *CD81*, *LRBA*, and *PRKCD* (protein kinase Cd).¹⁻³ Recently, germline heterozygous mutations in *NFKB2* were identified in 10 patients to be associated with early-onset CVID with autoimmunity in most cases,^{4,5} profound B-cell deficiency,⁶ or a CVID-like phenotype.⁷ All affected patients had hypogammaglobulinemia with variable association of the following clinical and immunologic features: central adrenal insufficiency (ACTH insufficiency), alopecia totalis or areata, trachyonychia, variable natural killer (NK) cell numbers, and defects in peripheral T and B cells. We report on a male patient with early-onset CVID who carried the heterozygous p.Arg853* mutation in *NFKB2* and later developed central adrenal insufficiency (ACTH insufficiency), alopecia totalis, and trachyonychia. An extensive immunologic work-up was performed that, besides confirming the presence of T- and B-cell defects, revealed, as a novel finding, impaired NK-cell cytotoxic activity *in vitro*, despite normal NK cell counts.

The index patient was born to Italian nonrelated parents. Routine laboratory investigation was performed at age 15 months for growth delay and showed profound hypogammaglobulinemia—IgG, 95 mg/dL (normal values for age, 264-1509 mg/dL); IgA, less than 5 mg/dL (normal values for age, 17-178 mg/dL); IgM, less than 5 mg/dL (normal values for age, 48-337 mg/dL)—in the presence of normal peripheral B-cell counts (CD19⁺, 16.5%). Immunoglobulin replacement treatment was initiated. During follow-up, the patient presented with occasional infections of the upper respiratory tract. He developed alopecia totalis at the age of 4 years, followed by the development of trachyonychia. Endocrinological evaluation following a hypoglycemic episode (blood glycemic level, 26 mg/dL) revealed ACTH and cortisol insufficiency for which he was placed on replacement treatment with hydrocortisone. During adolescence, he developed hypothyroidism and required hormone replacement therapy. On the identification of hypogammaglobulinemia, a more extensive immunologic work-up revealed abnormalities of both T and B cells, namely, an accumulation of T cells in the early stages of differentiation with reduction of the terminal stages of T-cell development, for both CD4 and CD8 subsets, and the typical peripheral B-cell block of CVID with reduction in memory B cells, both switched and IgM memory ones, and lack of plasma cells (Table I). Proliferative responses to mitogens were normal (Table I).

On the description of *NFKB2* mutations associated with early-onset CVID, ACTH insufficiency, alopecia totalis, and

TABLE I. Immunologic profile from the index patient mutated in *NFKB2*

Lymphocyte subsets	Index patient (%)	Normal range for age (%)
T cells (CD3 ⁺)	89.8	60.5-79.8
CD3 ⁺ CD4 ⁺	63.8	30.3-48.3
Naïve (CD45RA ⁺ CCR7 ⁺)	85.8	34.3-74.6
RTE (CD45RA ⁺ CCR7 ⁺ CD31 ⁺)	66.5	21.1-63.5
Central memory (CD45RA ⁺ CCR7 ⁺)	8.5	13.0-43.5
Effector memory (CD45RA ⁺ CCR7 ⁺)	4.4	8.5-28.1
Terminally differentiated (CD45RA ⁺ CCR7 ⁺)	1.2	0.7-6.6
CD3 ⁺ CD8 ⁺	22.3	13.8-37.5
Naïve (CD45RA ⁺ CCR7 ⁺)	92.0	26.7-72.9
Central memory (CD45RA ⁺ CCR7 ⁺)	1.8	1.2-11.6
Effector memory (CD45RA ⁺ CCR7 ⁺)	4.0	6.0-53.6
Terminally differentiated (CD45RA ⁺ CCR7 ⁺)	2.3	3.9-72.0
TCR γ/δ	1.7	0.5-21.5
B cells (CD19 ⁺)	4.8	5.7-19.7
RBE (CD38 ^{hi} CD21 ^{dim/lo} CD27 ⁺)	31.4	15.0-35.3
Naïve (CD38 ^{dim/lo} CD21 ^{hi} CD27 ⁺)	60.5	33.8-79.6
CD19 ^{hi} CD21 ^{lo}	1.9	1.1-10
Switched memory (IgD ⁺ CD27 ⁺)	0.4	2.7-20.6
IgM memory (IgD ⁺ CD27 ⁺)	2.0	3.5-24.1
Terminally differentiated (CD38 ^{hi} CD27 ^{hi} CD21 ^{lo})	0.17	0.16-8.70
Plasma cells (CD38 ^{hi} CD20 ⁺ CD138 ⁺)	0.00	0.04-3.20
NK cells (CD3 ⁺ CD16 ⁺ CD56 ⁺)	4.5	4.6-27.8

Proliferation (cpm)	Index patient	Healthy control
CD3	227,000	77,000
CD3 + IL2	200,000	152,000
PHA	116,000	120,000
PMA + Ionomycin	418,000	285,000
Background	4,000	7,000

PMA, Phorbol 12-myristate 13-acetate; RBE, recent bone marrow emigrants; RTE, recent thymic emigrants; TCR, T-cell receptor.

trachyonychia,^{4,5} direct gene sequencing for *NFKB2* was performed for the index patient. A c.2557C>T substitution was found, leading to the non-sense mutation p.Arg853* (Fig 1). This is a *de novo* mutation because the patient's parents were wild type for this mutation. Interestingly, all patients described so far to be mutated in *NFKB2*, with the exception of 3 family members carrying a missense mutation,⁶ carry *de novo* mutations.^{4,5,7} The p.Arg853* mutation is disease-causing and was identified in the first description of *NFKB2* mutations in CVID.⁴ The index patient here described is the 11th patient to be affected with this genetic defect and the second one to carry the p.Arg853* mutation. Interestingly, the index patient is the first patient with germline *NFKB2* mutation to develop clinically relevant hypothyroidism, underlying the clinical heterogeneity of this disorder. By reviewing the clinical data of the reported patients,⁴⁻⁷ it is evident that some clinical features are common to all patients, whereas others are sporadic (see Table E1 in this article's Online Repository at www.jacionline.org). Furthermore, the clinical and immunologic phenotype appears more severe in the presence of non-sense^{4,5,7} rather than missense⁶ mutations in *NFKB2*. Mutations in nuclear factor kappa B (NF-κB) essential




FIG 1. NFKB2 mutation and NK-cell evaluation. **A**, Electropherograms showing the *de novo* c.2557C>T mutation in NFKB2; the healthy parents resulted wild type for this mutation. **B**, NK-cell cytotoxicity *in vitro* activity from the index patient and a healthy donor. Freshly isolated PBMCs derived from healthy donors (□) and from patients (●) incubated overnight in the presence (IL-2 stimulated) or absence (unstimulated) of hr-IL-2 (100 U/mL) at different E/T ratios were tested against the K562 target cell line. The experiments were performed twice. **C**, Dot plots of CD69 expression on CD56⁺CD3[−] gated NK cells from the patient and a representative healthy control.

modifier, a component of the NF- κ B cascade, result in a complex form of immunodeficiency with variable clinical and immunologic severity depending on the type of mutations and have been previously reported to result in impaired NK-cell cytotoxicity.⁸ Although NF- κ B essential modifier is part of the canonical pathway, recent experimental data on NFKB2-mutated mice suggested that there may be overlap in the function of NF- κ B members in canonical and noncanonical pathway signaling.⁹ Because herpes viral susceptibility and numerical NK-cell abnormalities have been reported in NFKB2-mutated patients,^{4,5} we decided to evaluate whether mutations in NFKB2 could also affect NK-cell cytotoxic activity. NK-cell functional evaluation revealed defective NK-cell cytotoxic activity *in vitro*, which could not be restored by the addition of hr-IL-2 (Fig 1, B). Then, we further characterized the patient's NK cells by examining the expression pattern of activating and inhibitory NK receptors, including natural cytotoxicity receptors, NKG2D and killer cell immunoglobulin-like receptors molecules, chemokine receptors (CXCR1 and CCR7), and activation marker (CD69) on CD56⁺CD3[−] gated cells by flow cytometry. Patient's NK-cell subsets, both immature (CD56^{bright}) and mature (CD56^{dim}), showed normal expression of different NK receptors when compared with healthy donors (see Fig E1 in this article's [Online Repository](#) at www.jacionline.org). The expression of CD57, an NK-cell maturation marker, and the intracellular levels of perforin in CD56^{dim}CD16⁺KIR⁺ cells, the more differentiated and cytotoxic NK-cell population, were normal, ruling out a maturational defect (see Fig E1). On the contrary, the expression of CD69 on CD56^{dim}CD16⁺ in patient's NK cells was increased, suggesting an activated steady state of unknown cause (Fig 1, C).

Impaired NK-cell activity has been reported in numerous forms of primary immunodeficiencies.¹⁰ This is the first description of impaired NK-cell activity associated with NFKB2 mutations. These findings broaden the immunologic defects in NFKB2 deficiency, confirm the heterogeneous and complex immunologic and clinical phenotype in disorders in which NF- κ B components are defective, and underline an important role for NF- κ B in NK-cell cytotoxic activity.

We thank Fondazione Camillo Golgi and Comunità Bresciana, Brescia, Italy. We also thank the patients, their families, and the nurses for all their efforts. We thank Alessandro Moretta for providing mAbs anti-NK-cell receptors, produced in his Laboratory of Dipartimento di Medicina Sperimentale, Università di Genova, Italy.

Vassilios Lougaris, MD^a
Giovanna Tabellini, PhD^b
Massimiliano Vitali, PhD^a
Manuela Baronio, PhD^a
Ornella Patrizi, PhD^b
Giacomo Tampella, PhD^a
Augusto Biasini, MD^c
Daniele Moratto, PhD^a
Silvia Parolini, PhD^b
Alessandro Plebani, MD, PhD^a

From ^athe Pediatrics Clinic and Institute for Molecular Medicine "Angelo Nocivelli," Department of Clinical and Experimental Sciences, University of Brescia, Spedali Civili di Brescia, Brescia, Italy; ^bthe Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; and ^cthe Pediatrics Clinic, Maternal-Infantile Department, University of Bologna, Cesena, Italy. E-mail: vlougarisbs@yahoo.com.

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 (grant agreement no. 201549) (EURO-PADnet HEALTH-F2-2008-201549) and from the Italian Ministry of Health (grant no. GR-2010-2315762). The research leading to these results also received funding from the "Fondazione C. Golgi," Brescia.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

REFERENCES

1. Cunningham-Rundles C. Human B cells in perspective. *Immunol Res* 2012;54:227-32.
2. Salzer U, Warnatz K, Peter HH. Common variable immunodeficiency—an update. *Arthritis Res Ther* 2012;14:223.
3. Lougaris V, Tampella G, Baronio M, Vitali M, Plebani A. The genetic heterogeneity of common variable immunodeficiency (CVID): an update. *J Vaccines Vaccin* 2014;5:223.
4. Chen K, Coonrod EM, Kumánovics A, Franks ZF, Durtschi JD, Margraf RL, et al. Germline mutations in NFKB2 implicate the noncanonical NF- κ B pathway in the pathogenesis of common variable immunodeficiency. *Am J Hum Genet* 2013;93:812-24.
5. Liu Y, Hanson S, Gurugama P, Jones A, Clark B, Ibrahim MA. Novel NFKB2 mutation in early-onset CVID. *J Clin Immunol* 2014;34:686-90.
6. Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in non-processible p100. *Blood* 2014;124:2964-72.
7. Lindsley AW, Qian Y, Valencia CA, Shah K, Zhang K, Assa'ad A. Combined immune deficiency in a patient with a novel NFKB2 mutation. *J Clin Immunol* 2014;34:910-5.
8. Orange JS, Brodeur SR, Jain A, Bonilla FA, Schneider LC, Kretschmer R, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. *J Clin Invest* 2002;109:1501-9.
9. Tucker E, O'Donnell K, Fuchsberger M, Hilton AA, Metcalf D, Greig K, et al. A novel mutation in the Nfkb2 gene generates an NF-kappaB2 "super repressor" *J Immunol* 2007;179:7114-22.
10. Orange JS. Natural killer cell deficiency. *J Allergy Clin Immunol* 2013;132:515-25.

<http://dx.doi.org/10.1016/j.jaci.2014.11.038>




FIG E1. Flow cytometry analysis was performed on CD56⁺CD3⁻ gated cells derived from patient (*left columns*) and from healthy donor (*right columns*). Activating NK cell receptors (CD16, NKp46, NKp30, NKG2D), maturation markers of CD56dim NK cell population (CD57 and perforin content), HLA class I specific NK cell receptors (NKG2A, KIR molecules), CD56dim and CD56bright NK cell chemokine receptors (CXCR1 and CCR7 respectively) are shown. The slight differences regarding KIRs molecule expression between the index patient and the healthy donor fall within the physiologic variability.




FIG E1. (Continued).

TABLE E1. Clinical features of patients with germline *NFKB2* mutations*

Feature	Patient 1*	Patient 2*	Patient 3*	Patient 4*	Patient 5†	Patient 6†	Patient 7‡	Patient 8§	Patient 9§	Patient 10§	Patient 11
Sex	Female	Female	Male	Male	Female	Male	Male	Female	Male	Male	Male
Mutation	p.Lys855Serfs*7	p.Lys855Serfs*7	p.Lys855Serfs*7	p.Arg853*	p.Asp865Valfs*17	p.Asp865Valfs*17	p.A867Cfs*19	p.Asp865Gly	p.Asp865Gly	p.Asp865Gly	p.Arg853*
Age at diagnosis	30 y	6 y	3 y	10 y	9 y	7 y	2.5 y	40 y	20 y	Infancy	4 y
URTI	+	+	+	+	+	+	+	+	+	+	+
LRTI	+	–	+	+	+	–	+	+	–	–	–
Recurrent herpes infections	+	+	+	–	–	–	–	–	–	–	–
Alopecia universalis	–	+	–	+	–	–	+	+	+	+	+
								(Alopecia areata)	(Alopecia areata)	(Alopecia areata)	
ACTH deficiency	+	+	+	+	–	–	–	–	–	–	+
Hypothyroidism	–	–	–	–	–	–	–	–	–	–	+
Trachyonychia	–	+	–	+	–	–	+	–	–	–	+
Onychomycosis	–	+	–	–	–	–	–	–	–	–	–
Asthma	+	+	+	+	–	–	–	–	–	–	–

In all cases, except for patients 8, 9, and 10, the mutations are *de novo* mutations.

LRTI, Lower respiratory tract infection; URTI, upper respiratory tract infection.

*Chen et al.⁴

†Liu et al.⁵

‡Lindsley et al.⁶

§Lee et al.⁷

||Index patient.